Lee S. Schwartzberg, MD of University of Tennessee Health Science Center explains the use of genomic profiling for prognoses in breast cancer, which shows the chances of relapse and a prediction for endocrine therapy or chemotherapy. He states that with genomic profiling, oncologists can tailor their treatments based on these results. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.
Using Genomic Profiling for Prognoses in Breast Cancer
